Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance

Immune checkpoint inhibitors (ICIs), although promising, have variable benefit in head and neck cancer (HNC). We noted that tumor galectin-1 (Gal1) levels were inversely correlated with treatment response and survival in patients with HNC who were treated with ICIs. Using multiple HNC mouse models,...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Clin Invest
Main Authors: Nambiar, Dhanya K., Aguilera, Todd, Cao, Hongbin, Kwok, Shirley, Kong, Christina, Bloomstein, Joshua, Wang, Zemin, Rangan, Vangipuram S., Jiang, Dadi, von Eyben, Rie, Liang, Rachel, Agarwal, Sonya, Colevas, A. Dimitrios, Korman, Alan, Allen, Clint T., Uppaluri, Ravindra, Koong, Albert C., Giaccia, Amato, Le, Quynh Thu
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society for Clinical Investigation 2019
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6877340/
https://ncbi.nlm.nih.gov/pubmed/31710313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI129025
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים